Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về y học đề tài: Antithrombin III in patients admitted to intensive care units: a multicenter observational study. | Available online http content 6 5 447 Research Antithrombin III in patients admitted to intensive care units a multicenter observational study Andrea Messori1 Franca Vacca2 Monica Vaiani2 Sabrina Trippoli2 and the Gruppo di Studio sull antitrombina III Coordinator Laboratorio SIFO di Farmacoeconomia c o Drug Information Center Azienda Ospedaliera Careggi Florence Italy 2Researcher Laboratorio SIFO di Farmacoeconomia c o Drug Information Center Azienda Ospedaliera Careggi Florence Italy Correspondence Andrea Messori md3439@ Received 8 January 2002 Revisions requested 4 March 2002 Revisions received 18 May 2002 Accepted 20 June 2002 Published 24 July 2002 Critical Care 2002 6 447-451 This article is online at http content 6 5 447 2002 Messori et al. licensee BioMed Central Ltd Print ISSN 1364-8535 Online ISSN 1466-609X Abstract Introduction The administration of antithrombin III ATIII is useful in patients with congenital deficiency but evidence for the other therapeutic indications of this drug is still uncertain. In Italy the use of ATIII is very common in intensive care units ICUs . For this reason we undertook an observational study to determine the pattern of use of ATIII in ICUs and to assess the outcome of patients given this treatment. Methods From 20 May to 20 July 2001 all consecutive patients admitted to ICUs in 20 Italian hospitals and treated with ATIII were enrolled. The following information was recorded from each patient congenital deficiency indication for use of ATIII daily dose and duration of ATIII treatment outcome of hospitalization alive or dead . The outcome data of our observational study were compared with those reported in previously published randomized controlled trials RCTs . Results Two hundred and sixteen patients were enrolled in the study. The clinical indications for using ATIII were sepsis disseminated intravascular coagulation and other clinical conditions . At the end of the study .
